Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian Patients)

被引:18
作者
Arfaoui-Toumi, A. [1 ]
Kria-Ben Mahmoud, L. [1 ]
Ben Hmida, M. [2 ]
Khalfallah, M. -T. [3 ]
Regaya-Mzabi, S. [4 ]
Bouraoui, S. [1 ,4 ]
机构
[1] Mongi Slim Hosp, Lab Colorectal Canc Res UR03ES04, Tunis, Tunisia
[2] Med Univ Tunis, Dept Epidemiol & Prevent Med, Tunis, Tunisia
[3] Mongi Slim Hosp, Dept Surg, Tunis, Tunisia
[4] Mongi Slim Hosp, Dept Pathol, Div Cellular Oncol, Tunis, Tunisia
关键词
colon cancer; galectin-3; mucinous carcinomas; immunochemistry; HUMAN COLON-CANCER; CARBOHYDRATE-BINDING PROTEIN-35; 67-KD LAMININ RECEPTOR; DIFFERENTIAL EXPRESSION; NEOPLASTIC PROGRESSION; DECREASED EXPRESSION; CELL-MIGRATION; CARCINOMA; ADENOCARCINOMA; MODULATION;
D O I
10.1684/bdc.2010.1032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Galectin-3 is a specific soluble lectin of the beta-galactoside family. It plays an important role in cell adherence, proliferation, and differentiation. It has also been shown that galectin-3 expression correlates with tumor progression in several types of cancers. We investigated the involvement of galectin-3 in colorectal cancer development. We performed a comparative immunohistochemical analysis of galectin-3 expression in term of intensity and distribution in normal mucosa, in primary tumor and in metastasis from 200 patients with colorectal cancer selected among 325 cases. We also compared the galectin-3 staining according to the histological subtype (mucinous vs non mucinous), tumoral differentiation and stage of tumor. We showed a strong and diffuse positive staining of galectin-3 in both adjacent and distanced normal mucosa, in well differentiated adenocarcinoma and in metastasis. However, we note a progressive decrease of galectin-3 staining according to the decreasing degree of tumoral differentiation. We also observed a loss of this protein in adenocarcinoma with mucinous component < 50%, where the positive staining was limited only to the well differentiated areas of tumor. These data suggest that galectin-3 play an important role in colorectal cancer progression concerning the non mucinous carcinoma and can be used as a prognostic factor to predict poor outcome of patients. In mucinous subtype, galectin-3 might be implicated in one or many step of its genesis perhaps through the control of cellular adhesion and interaction with mucin produced. Adenocarcinoma with mucinous component < 50% would be integrate to mucinous carcinoma, not to non mucinous ones. These investigations could open perspectives for therapeutic means targeted to improve the prognosis of this neoplasm.triangle
引用
收藏
页码:E1 / E8
页数:8
相关论文
共 42 条
[1]  
BARONDES SH, 1994, J BIOL CHEM, V269, P20807
[2]  
Bresalier RS, 1996, CANCER RES, V56, P4354
[3]   Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3 [J].
Bresalier, RS ;
Mazurek, N ;
Sternberg, LR ;
Byrd, JC ;
Yunker, CK ;
Nangia-Makker, P ;
Raz, A .
GASTROENTEROLOGY, 1998, 115 (02) :287-296
[4]  
Castronovo V, 1996, J PATHOL, V179, P43, DOI 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO
[5]  
2-N
[6]   INVERSE MODULATION OF STEADY-STATE MESSENGER-RNA LEVELS OF 2 NONINTEGRIN LAMININ-BINDING PROTEINS IN HUMAN COLON-CARCINOMA [J].
CASTRONOVO, V ;
CAMPO, E ;
VANDENBRULE, FA ;
CLAYSMITH, AP ;
CIOCE, V ;
LIU, FT ;
FERNANDEZ, PL ;
SOBEL, ME .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (15) :1161-1169
[7]   Galectins and cancer [J].
Danguy, A ;
Camby, I ;
Kiss, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2002, 1572 (2-3) :285-293
[8]   Expression of human intestinal mucin is modulated by the β-galactoside binding protein galectin-3 in colon cancer [J].
Dudas, SP ;
Yunker, CK ;
Sternberg, LR ;
Byrd, JC ;
Bresalier, RS .
GASTROENTEROLOGY, 2002, 123 (03) :817-826
[9]   Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy [J].
Goh, KL ;
Quek, KF ;
Yeo, GTS ;
Hilmi, IN ;
Lee, CK ;
Hasnida, N ;
Aznan, M ;
Kwan, KL ;
Ong, KT .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (09) :859-864
[10]  
Gong HC, 1999, CANCER RES, V59, P6239